R. M, P. PH, R. MH. A prospective analysis of the cost-effectiveness of alfuzosin, tamsulosin and silodosin for 12 weeks in benign prostatic hyperplasia. Int J Basic Clin Pharmacol [Internet]. 2016 Dec. 21 [cited 2026 Apr. 16];5(6):2481-7. Available from: https://www.ijbcp.com/index.php/ijbcp/article/view/37